$125 Million

Prevail Therapeutics, Inc.

Initial Public Offering

Bookrunner, June 2019

Prevail Therapeutics is a company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The Company is applying a precision medicine approach to neurodegeneration, which it believes will increase the probability of creating disease-modifying therapies that improve patient outcomes. The Company’s differentiated approach to gene therapy is designed to mitigate challenges faced by others in the development of therapeutics for the CNS. Prevail selects targets for diseases that correspond to patient populations with particular genetic mutations that it believes can be treated by increasing or decreasing the expression of a particular gene. Prevail’s lead program is PR001 for the treatment of Parkinson’s disease with at least one GBA1 mutation (PD-GBA) and neuronopathic (Type 2 and Type 3) Gaucher disease. Prevail is developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation (FTD-GRN) and PR004 for the treatment of synucleinopathies.